BioSpace News Archive

Foresee pharmaceuticals (TPEx: 6576.TWO) (“Foresee”) announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from the offering were approximately US$47 million ( NT$1.32 billion ). The pro

Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government steering committee for therapeutic clinical trials and other research (CAPNET). In the context of a substant

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced that it will ring the Nasdaq opening bell on December 28, 2020, in celebration of its recently completed initial public offering.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biote

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) today announced that it received a waiver letter from SWK Funding LLC (“SWK”) related to the required Minimum Revenue Covenant for Q4-2020 in its existing credit facility with Acerus. All other terms and conditions in the SWK loan agreement remain unchanged. About Acerus Acerus Pharmaceuticals Corporation is a Canadian-based

COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure Phase 2/3 clinical trials by COVAXX t

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming 39 th Annual J.P. Morgan Healthcare Conference. M

Aurobindo Pharma has exclusive rights to develop and commercialize UB-612 in India and to UNICEF and non-exclusive rights in other select emerging markets Expected to support up to 480 million doses of UB-612 for India and other countries Agreement leverages Aurobindo Pharma’s existing development, commercial and manufacturing infrastructure

Oragenics, Inc., a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced it has entered into definitive agreements with investors for the purchase and sale of 14,444,444 shares of its common stock at a purchase price of $0.45 per share in a registered direct offering.

Interscope, Inc. announced today the receipt of FDA de novo clearance to market its EndoRotor® System in the United States for direct endoscopic necrosectomy (DEN), a minimally invasive treatment